Enterprise Value
2.892M
Cash
3.23M
Avg Qtr Burn
-756.4K
Short % of Float
0.92%
Insider Ownership
68.97%
Institutional Own.
11.10%
Qtr Updated
06/30/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Tecarfarin Details Systemic thromboembolism, End-Stage Renal Disease , Atrial fibrillation | Phase 3 Initiation |